EUVIMEDEUVIMED entdecken
Crossref

Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease

Kazuichi Okazaki, Tsukasa Ikeura, Kazushige Uchida

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Kazuichi Okazaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Osaka, Japan. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Autoimmune Pancreatitis, Pancreatitis, Autoimmune Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Ministry of Culture and Science of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder recognized as a novel clinical entity with either synchronous or metachronous multiorgan involvement. Autoimmune pancreatitis (AIP) is classified into two types: type 1 AIP as a pancreatic manifestation of IgG4-RD and type 2 AIP with granulocytic epithelial lesion and occasional association with ulcerative colitis. Although the pathogenic mechanism still remains unclear, possible multipathogenic factors such as genetic factors, disease-specific or related antigens, and abnormal innate or adaptive immunity may be involved in the development of IgG4-RD. Many immunocytes including M2 macrophages, plasmablasts, B cells, and T-cells (Th2-CD4+T, follicular helper T-cells, and CD4+SLAMF7+cytotoxic T-cells) play important roles in the pathogenesis. Conventional induction and maintenance therapies with glucocorticoid or rituximab are recommended in all symptomatic patients with active IgG4-RD. In those at risk for irreversible damage in any organs, this should be done urgently, regardless of symptoms. As no randomized clinical trials other than glucocorticoid maintenance therapy for type 1 AIP have been performed, the comprehensive management for IgG4-RD has not been established yet. Targeted treatment approaches against the plasmablast to B cell lineage and the CD4+ SLAMF7+ cytotoxic T-cell seem to be promising for the future-directed treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin G4-Related DiseaseAutoimmune PancreatitisPancreatitisAutoimmune DiseasesHumansGlucocorticoidsCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

Autoimmune pancreatitisIgG4-related diseasesteroid

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.

Förderung

  • Ministry of Culture and Science of Japan

Zitieren

APA

Okazaki, K., Ikeura, T., & Uchida, K. (2023). Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease. Modern Rheumatology. https://doi.org/10.1093/mr/roac054

Vancouver

Okazaki K, Ikeura T, Uchida K. Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease. Modern Rheumatology. 2023. doi:10.1093/mr/roac054

BibTeX
@article{Okazaki2023,
  author = {Okazaki, Kazuichi and Ikeura, Tsukasa and Uchida, Kazushige},
  title = {Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac054}
}
Kostenlos starten →